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What is Selective Crossover?
• • 25% crossed over • Because of selective crossover and based on external evidence showing the benefit of switching from tamoxifen to an aromatase inhibitor, the ITT analysis on updated data from BIG 1-98 is inaccurate and no longer relevant for patient care • Modeling methods such as IPCW should be used to estimate outcome that would have been observed had there been no selective crossover • BIG 1-98 provides evidence of a statistically significant (p<0.05) overall survival benefit for 5 years of letrozole compared with 5 years of tamoxifen
